

Diana Romero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9316989/publications.pdf>

Version: 2024-02-01

58
papers

196
citations

1478505

6
h-index

1199594

12
g-index

59
all docs

59
docs citations

59
times ranked

540
citing authors

#	ARTICLE	IF	CITATIONS
1	Benefit of nectin-4 targeting with enfortumab vedotin confirmed. Nature Reviews Urology, 2021, 18, 190-190.	3.8	3
2	Inhibition of TGF β 2 enhances immune-checkpoint blockade. Nature Reviews Clinical Oncology, 2018, 15, 201-201.	27.6	3
3	Metronomic chemotherapy for elderly and/or frail patients. Nature Reviews Clinical Oncology, 2018, 15, 266-266.	27.6	9
4	DDR signature to predict response to ICI. Nature Reviews Clinical Oncology, 2018, 15, 346-346.	27.6	2
5	CheckMate 214 " a winning combination?. Nature Reviews Clinical Oncology, 2018, 15, 343-343.	27.6	1
6	Improved pain management. Nature Reviews Clinical Oncology, 2018, 15, 346-346.	27.6	0
7	Oncolytic viruses prime antitumour immunity. Nature Reviews Clinical Oncology, 2018, 15, 135-135.	27.6	17
8	Genomic information improves risk prediction. Nature Reviews Urology, 2018, 15, 68-68.	3.8	4
9	Genomic information improves risk prediction. Nature Reviews Clinical Oncology, 2018, 15, 66-67.	27.6	1
10	Favourable outcomes with CAR T cells. Nature Reviews Clinical Oncology, 2018, 15, 65-65.	27.6	7
11	Time for adjuvant vemurafenib?. Nature Reviews Clinical Oncology, 2018, 15, 265-265.	27.6	2
12	Nice to see you " evolving MHC "peptide presentation. Nature Reviews Clinical Oncology, 2018, 15, 5-5.	27.6	2
13	Relying on quality over quantity. Nature Reviews Clinical Oncology, 2018, 15, 7-7.	27.6	1
14	Oesophageal cancer " not all alike. Nature Reviews Clinical Oncology, 2017, 14, 138-138.	27.6	3
15	Platelets to the rescue. Nature Reviews Clinical Oncology, 2017, 14, 140-140.	27.6	8
16	Fitness depends on KRAS imbalance. Nature Reviews Clinical Oncology, 2017, 14, 262-263.	27.6	0
17	Idelalisib for CLL " risky benefit. Nature Reviews Clinical Oncology, 2017, 14, 199-199.	27.6	2
18	Dual targeting to defeat resistance. Nature Reviews Clinical Oncology, 2017, 14, 328-328.	27.6	1

#	ARTICLE	IF	CITATIONS
19	Tracing tumour evolution. Nature Reviews Clinical Oncology, 2017, 14, 391-391.	27.6	0
20	A CAR T-cell recipe for success. Nature Reviews Clinical Oncology, 2017, 14, 330-330.	27.6	2
21	Olaparib improves PFS. Nature Reviews Clinical Oncology, 2017, 14, 460-460.	27.6	0
22	KEYNOTE-001 " combo improves melody. Nature Reviews Clinical Oncology, 2017, 14, 393-393.	27.6	3
23	Unravelling intertwined second-line options. Nature Reviews Clinical Oncology, 2017, 14, 197-197.	27.6	0
24	PALOMA-2 " hope beyond the threshold. Nature Reviews Clinical Oncology, 2017, 14, 1-1.	27.6	11
25	Benefit with anti-PD-L1. Nature Reviews Clinical Oncology, 2017, 14, 71-71.	27.6	1
26	Extended EFS with rituximab. Nature Reviews Clinical Oncology, 2017, 14, 714-714.	27.6	1
27	Importantly, less is effective. Nature Reviews Clinical Oncology, 2017, 14, 585-585.	27.6	0
28	Reality check for nivolumab in advanced-stage melanoma. Nature Reviews Clinical Oncology, 2017, 14, 525-525.	27.6	1
29	Establishing a family tree. Nature Reviews Clinical Oncology, 2017, 14, 525-525.	27.6	0
30	After ibrutinib, CAR T cells induce responses. Nature Reviews Clinical Oncology, 2017, 14, 588-588.	27.6	3
31	Feasible mutation-targeted therapy. Nature Reviews Clinical Oncology, 2017, 14, 460-460.	27.6	0
32	Keeping aFLOaT with new combination. Nature Reviews Clinical Oncology, 2017, 14, 4-4.	27.6	3
33	Tracing stem cells in oligodendroglioma. Nature Reviews Clinical Oncology, 2017, 14, 3-3.	27.6	1
34	Cytarabine " new standard of care for MCL. Nature Reviews Clinical Oncology, 2016, 13, 464-465.	27.6	3
35	Atezolizumab becomes POPLAR. Nature Reviews Clinical Oncology, 2016, 13, 266-266.	27.6	5
36	Chemoresistance " a little help from friends. Nature Reviews Clinical Oncology, 2016, 13, 329-329.	27.6	0

#	ARTICLE	IF	CITATIONS
37	Dressed to ImpREsSs. Nature Reviews Clinical Oncology, 2016, 13, 263-263.	27.6	0
38	Improvements with daratumumab. Nature Reviews Clinical Oncology, 2016, 13, 592-592.	27.6	1
39	Here or there, PD-L1 can be anywhere. Nature Reviews Clinical Oncology, 2016, 13, 530-530.	27.6	0
40	High-risk SMM " early action required. Nature Reviews Clinical Oncology, 2016, 13, 529-529.	27.6	0
41	CTC heterogeneity is dynamic. Nature Reviews Clinical Oncology, 2016, 13, 654-654.	27.6	6
42	Follow your PET for guidance. Nature Reviews Clinical Oncology, 2016, 13, 463-463.	27.6	0
43	Precision or imprecision medicine?. Nature Reviews Clinical Oncology, 2016, 13, 713-713.	27.6	5
44	TOURMALINE " new gem unearthed in the MM treatment landscape. Nature Reviews Clinical Oncology, 2016, 13, 398-398.	27.6	0
45	CAR T cells ready to go mainstream. Nature Reviews Clinical Oncology, 2016, 13, 397-397.	27.6	6
46	Treatment choice " size matters. Nature Reviews Clinical Oncology, 2016, 13, 66-66.	27.6	4
47	PD-1 says goodbye, TIM-3 says hello. Nature Reviews Clinical Oncology, 2016, 13, 203-203.	27.6	50
48	MRD assessment " guiding decisions for patients with AML. Nature Reviews Clinical Oncology, 2016, 13, 136-136.	27.6	3
49	Divergence shapes recurrence. Nature Reviews Clinical Oncology, 2016, 13, 136-136.	27.6	0
50	Eribulin " a welcomed advance. Nature Reviews Clinical Oncology, 2016, 13, 204-204.	27.6	3
51	ETV6 germline mutation " a risk for ALL. Nature Reviews Clinical Oncology, 2016, 13, 4-4.	27.6	2
52	Targeted agents: efficacy RESONATEs better with fine tuning. Nature Reviews Clinical Oncology, 2016, 13, 63-63.	27.6	0
53	mDCF "new standard-of-care?. Nature Reviews Clinical Oncology, 2015, 12, 686-686.	27.6	0
54	Tracking ctDNA to evaluate relapse risk. Nature Reviews Clinical Oncology, 2015, 12, 624-624.	27.6	9

#	ARTICLE	IF	CITATIONS
55	Nivolumabâ€”an effective second-line treatment for NSCLC. Nature Reviews Clinical Oncology, 2015, 12, 685-685.	27.6	5
56	Rolapitantâ€”a new and safer antiemetic agent. Nature Reviews Clinical Oncology, 2015, 12, 562-562.	27.6	1
57	Promising results of BCL2 inhibition. Nature Reviews Clinical Oncology, 2015, 12, 504-504.	27.6	1
58	Improving prediction of relapse risk. Nature Reviews Clinical Oncology, 2015, 12, 564-564.	27.6	0